The company recently reported its full-year 2025 results, showing a net loss of $19.5 million. However, it maintains a cash position of $28.2 million , which is expected to support operations through the initiation of the enVVe pivotal trials in 2026.
Wall Street is divided. While the consensus rating is a "Buy" with an average price target of $13.46 , some major firms like Bank of America and Wells Fargo have more cautious targets of $6.00 , citing manufacturing hurdles and long qualification cycles for smartphones. Summary Table: Quick Comparison (April 2026) enVVeno Medical (ENVV) Enovix (ENVX) Primary Focus Medical Devices (Venous Valves) Next-Gen Silicon-Anode Batteries Recent Price ~$5.10 (as of 4/27/26) ~$6.51 (as of 4/27/26) Outlook High-risk trial phase Scaling manufacturing in Malaysia Catalysts enVVe pivotal trial start Q1 Earnings on May 13, 2026 buy envv stock
While the ticker "ENVV" commonly brings to mind , recent market activity has also heavily focused on Enovix (ENVX) , a next-gen battery tech company often discussed alongside high-growth tech stocks. Both companies currently present high-risk, high-reward opportunities as of late April 2026. enVVeno Medical (ENVV): The Biotech High-Roller The company recently reported its full-year 2025 results,
Are you more interested in the of enVVeno or the hardware scalability of Enovix for your portfolio? While the consensus rating is a "Buy" with